Urogen Pharma (URGN) Competitors

Urogen Pharma currently has a consensus price target of $34.13, indicating a potential upside of 43.20%. Indivior has a consensus price target of $39.33, indicating a potential downside of 0.65%. Given Urogen Pharma's higher probable upside, equities analysts plainly believe Urogen Pharma is more favorable than Indivior.

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 4.7% of Urogen Pharma shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Urogen Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

In the previous week, Indivior had 17 more articles in the media than Urogen Pharma. MarketBeat recorded 20 mentions for Indivior and 3 mentions for Urogen Pharma. Indivior's average media sentiment score of 0.81 beat Urogen Pharma's score of 0.42 indicating that Indivior is being referred to more favorably in the news media.

Indivior has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Indivior has a net margin of 19.44% compared to Urogen Pharma's net margin of -139.81%. Urogen Pharma's return on equity of 0.00% beat Indivior's return on equity.

Urogen Pharma currently has a consensus price target of $34.13, indicating a potential upside of 43.20%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 7.26%. Given Urogen Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Urogen Pharma is more favorable than Kiniksa Pharmaceuticals International.

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 4.7% of Urogen Pharma shares are held by insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Urogen Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

In the previous week, Kiniksa Pharmaceuticals International had 33 more articles in the media than Urogen Pharma. MarketBeat recorded 36 mentions for Kiniksa Pharmaceuticals International and 3 mentions for Urogen Pharma. Kiniksa Pharmaceuticals International's average media sentiment score of 0.66 beat Urogen Pharma's score of 0.42 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Urogen Pharma's net margin of -139.81%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Urogen Pharma's return on equity.

Amneal Pharmaceuticals has a net margin of 4.53% compared to Urogen Pharma's net margin of -139.81%. Urogen Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Urogen Pharma has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Urogen Pharma currently has a consensus price target of $34.13, indicating a potential upside of 43.20%. Amneal Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 11.86%. Given Urogen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Urogen Pharma is more favorable than Amneal Pharmaceuticals.

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Urogen Pharma. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 3 mentions for Urogen Pharma. Amneal Pharmaceuticals' average media sentiment score of 0.75 beat Urogen Pharma's score of 0.42 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.7% of Urogen Pharma shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by company insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Urogen Pharma has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Urogen Pharma has a net margin of -139.81% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. Urogen Pharma's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

In the previous week, Crinetics Pharmaceuticals had 9 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 3 mentions for Urogen Pharma. Crinetics Pharmaceuticals' average media sentiment score of 0.96 beat Urogen Pharma's score of 0.42 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Urogen Pharma presently has a consensus price target of $34.13, indicating a potential upside of 43.20%. Crinetics Pharmaceuticals has a consensus price target of $76.75, indicating a potential upside of 88.34%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Urogen Pharma.

Urogen Pharma has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.